Zymaxid Drug Patent Profile
✉ Email this page to a colleague
When do Zymaxid patents expire, and what generic alternatives are available?
Zymaxid is a drug marketed by Abbvie and is included in one NDA.
The generic ingredient in ZYMAXID is gatifloxacin. There are sixteen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the gatifloxacin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Zymaxid
A generic version of Zymaxid was approved as gatifloxacin by LUPIN LTD on August 28th, 2013.
Summary for Zymaxid
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 140 |
| Clinical Trials: | 1 |
| Patent Applications: | 4,513 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for Zymaxid |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for Zymaxid |
| What excipients (inactive ingredients) are in Zymaxid? | Zymaxid excipients list |
| DailyMed Link: | Zymaxid at DailyMed |
Recent Clinical Trials for Zymaxid
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Toyos Clinic | |
| Discover Vision Centers |
Pharmacology for Zymaxid
| Drug Class | Quinolone Antimicrobial |
Anatomical Therapeutic Chemical (ATC) Classes for Zymaxid
Paragraph IV (Patent) Challenges for ZYMAXID
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| ZYMAXID | Ophthalmic Solution | gatifloxacin | 0.5 % | 022548 | 1 | 2010-12-07 |
US Patents and Regulatory Information for Zymaxid
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie | ZYMAXID | gatifloxacin | SOLUTION/DROPS;OPHTHALMIC | 022548-001 | May 18, 2010 | AT | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Zymaxid
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Abbvie | ZYMAXID | gatifloxacin | SOLUTION/DROPS;OPHTHALMIC | 022548-001 | May 18, 2010 | ⤷ Try a Trial | ⤷ Try a Trial |
| Abbvie | ZYMAXID | gatifloxacin | SOLUTION/DROPS;OPHTHALMIC | 022548-001 | May 18, 2010 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Zymaxid
See the table below for patents covering Zymaxid around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Taiwan | 537895 | ⤷ Try a Trial | |
| World Intellectual Property Organization (WIPO) | 9619472 | ⤷ Try a Trial | |
| Japan | H08176143 | 8-ALKOXYQUINOLONECARBOXYLIC ACID HYDRATE HAVING EXCELLENT STABILITY AND ITS PRODUCTION | ⤷ Try a Trial |
| Spain | 2264266 | ⤷ Try a Trial | |
| Germany | 69932313 | ⤷ Try a Trial | |
| Canada | 2208704 | HYDRATE D'ACIDE 8-ALCOXYQUINOLONECARBOXYLIQUE AYANT UNE EXCELLENTE STABILITE ET PROCEDE DE FABRICATION (8-ALKOXYQUINOLONECARBOXYLIC ACID HYDRATE WITH EXCELLENT STABILITY AND PROCESS FOR PRODUCING THE SAME) | ⤷ Try a Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for Zymaxid
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0230295 | C300110 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: GATIFLOXACINUM, DESGEWENST IN DE VORM VAN EEN HYDRAAT, ZUURADDITIEZOUT OF ALKALISCH ZOUT, IN HET BIJZONDER GATIFLOXACINUM SESQUIHYDRICUM; REGISTRATION NO/DATE: DE 48870.00.00, 48870.01.00, 48872.00.00, 48872.01.00, 48874.00.00, 48874.01.00, 48876.00.00, 48876.01.00 20011022 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
